Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis, Inc. (NASDAQ: CRIS) announces it will release its fourth quarter 2022 financial results on March 9, 2023, following the close of U.S. markets. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results. Curis focuses on developing innovative cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech. Notably, the FDA has placed a partial clinical hold on Curis's TakeAim Leukemia trial, affecting patient enrollment for some phases. For more details, visit Curis's website.
Curis announced positive updates from the Phase 1a study of emavusertib (CA-4948) in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (hrMDS). In patients with FLT3 mutations, a 29% complete remission (CR) rate was noted, while those with spliceosome mutations saw a CR/CRh rate of 22%. Additionally, an overall response rate (ORR) of 45% was recorded in hrMDS patients. Emavusertib is also being evaluated in combination with venetoclax. The company plans to discuss a recommended Phase 2 dose with the FDA by mid-2023.
Curis, Inc. (NASDAQ: CRIS) will host a webcast on December 12, 2022, at 10:00 a.m. ET, to discuss new data from the TakeAim Leukemia trial involving emavusertib, presented at the 64th American Society of Hematology Annual Meeting. This session will include results from 28 additional evaluable AML/MDS patients, focusing on those treated with emavusertib as monotherapy and in combination with venetoclax. The call will feature leadership presentations and a Q&A session.
Curis, Inc. (NASDAQ: CRIS) reported its third-quarter 2022 business update, focusing on the development of emavusertib for relapsed or refractory acute myeloid leukemia. The company will present additional data at ASH 2022, highlighting a total of 24 patients treated. Curis plans to concentrate resources on emavusertib, reducing its workforce by approximately 30% and extending its cash runway into 2025. Financially, Curis reported a net loss of $13.3 million for Q3 2022, with net revenues of $2.8 million. Cash and investments totaled $98.7 million as of September 30, 2022.
Curis, Inc. (NASDAQ: CRIS) announced its participation in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) in Boston, showcasing three significant research posters. Key highlights include a presentation on emavusertib, an IRAK4 inhibitor, detailing its therapeutic potential for melanoma brain metastases. Additionally, two presentations on CI-8993, an anti-VISTA antibody, focus on its pharmacokinetic and pharmacodynamic profiles. These presentations aim to enhance understanding of their roles in cancer treatment.
Curis, Inc. (NASDAQ: CRIS) plans to report its third quarter 2022 financial results on November 9, 2022, after U.S. market closure. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the results. Curis is known for developing innovative cancer therapeutics, including collaborations on various immuno-oncology projects. Notably, the TakeAim Leukemia trial of emavusertib is on a partial clinical hold, impacting new patient enrollment.
On October 3, 2022, Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options for 121,650 shares to two new employees. These options have an exercise price equal to the stock's closing price on that date, a 10-year term, and vest over four years. This grant was made outside of the company's existing stock incentive plan as a material inducement for employment. Curis specializes in innovative cancer therapeutics, including partnerships for developing novel treatments like emavusertib, currently in clinical trials for hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) will host the 1st Symposium on IRAK4 in Cancer on October 7, 2022, from 9:00 am to 1:00 pm ET. The virtual event, led by renowned experts, will explore the role of IRAK4, a promising target for cancer treatment, particularly in hematologic malignancies. CEO James Dentzer emphasized IRAK4's potential as an immunotherapy target. The agenda includes discussions on IRAK4 biology, mechanisms in cancer, and therapeutic strategies involving IRAK4 inhibitors.
Curis, Inc. (NASDAQ: CRIS) has announced the 2nd Annual VISTA Symposium, scheduled for September 23, 2022, from 9:00 am to 1:00 pm ET, focusing on VISTA in cancer treatment. Hosted by Dr. Randolph Noelle, the symposium will feature discussions on VISTA biology, immune evasion, and therapeutic strategies. CEO James Dentzer emphasized Curis's leading role in VISTA research, highlighting progress with their program CI-8993. The event will bring together global experts to advance understanding and treatment options for cancer patients.
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 4:00 p.m. ET in New York, NY. He will also attend the Cantor Oncology and HemOnc Conference on September 28, 2022, at 3:25 p.m. ET. A webcast of the H.C. Wainwright presentation will be available on the Curis website for 90 days post-event. Curis is developing innovative cancer therapies, including emavusertib, currently in clinical trials.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?